Psychopharmacology Practice Questions

Q: Which of the following conditions is considered a first-line treatment for SSRI?

Social phobia. **Explanation:** Selective Serotonin Reuptake Inhibitors (SSRIs) are the established **first-line pharmacological treatment** for a wide spectrum of anxiety and obsessive-compulsive disorders. However, in the context of this specific question, **Social Phobia (Social Anxiety Disorder)** is highlighted as a primary indication where SSRIs are the gold standard for long-term management. **Why Social Phobia is Correct:** SSRIs (such as Escitalopram, Sertraline, and Paroxetine) are the first-line agents because they effectively address both the cognitive symptoms (fear of scrutiny) and the functional impairment associated with the disorder. While Beta-blockers (Propranolol) are used for "performance anxiety," SSRIs are the treatment of choice for the generalized form of Social Phobia. **Analysis of Other Options:** * **Obsessive-Compulsive Disorder (OCD):** While SSRIs are first-line, they often require **higher doses** and a longer duration (10–12 weeks) to show a response compared to anxiety disorders. * **Panic Disorder:** SSRIs are first-line; however, treatment often starts at very low doses to avoid "jitteriness syndrome" (initial worsening of anxiety). * **Post-Traumatic Stress Disorder (PTSD):** SSRIs (Sertraline, Fluoxetine) are first-line, but the treatment approach often heavily emphasizes trauma-focused psychotherapy (CBT/EMDR) alongside medication. **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** SSRIs are the DOC for OCD, Panic Disorder, Social Phobia, PTSD, and GAD. * **OCD Specifics:** Fluoxetine is often preferred; Clomipramine (TCA) is the most effective but is second-line due to its side-effect profile. * **Side Effects:** Sexual dysfunction (most common long-term), GI upset, and Sleep disturbances. * **Black Box Warning:** Increased risk of suicidal ideation in children and young adults.

Q: Selective serotonin reuptake inhibitors are drugs of choice for all of the following conditions except:

Acute panic attack. **Explanation:** The correct answer is **Acute panic attack** because of the difference between immediate symptom relief and long-term maintenance therapy. **1. Why "Acute Panic Attack" is the correct answer:** Selective Serotonin Reuptake Inhibitors (SSRIs) have a **delayed onset of action**, typically taking 2 to 4 weeks to manifest therapeutic effects. In an "acute" panic attack, the patient requires immediate stabilization. The drugs of choice for immediate relief are **Benzodiazepines** (e.g., Alprazolam or Lorazepam) due to their rapid GABA-mediated sedative and anxiolytic effects. While SSRIs are the drug of choice for *Panic Disorder* (long-term prevention), they are ineffective for an active, acute episode. **2. Why the other options are incorrect:** SSRIs are considered the first-line treatment (Drug of Choice) for the following chronic anxiety conditions because of their efficacy and superior safety profile compared to older antidepressants: * **Social Phobia (Social Anxiety Disorder):** SSRIs are first-line for long-term management. * **Post-Traumatic Stress Disorder (PTSD):** SSRIs (specifically Sertraline and Paroxetine) are the primary pharmacological intervention. * **Generalized Anxiety Disorder (GAD):** SSRIs are preferred for sustained control of symptoms. **Clinical Pearls for NEET-PG:** * **DOC for OCD:** SSRIs (usually in higher doses than for depression). * **DOC for Bulimia Nervosa:** Fluoxetine. * **Common Side Effects:** Sexual dysfunction (most common long-term), GI upset, and "jitteriness syndrome" (initial worsening of anxiety). * **Serotonin Syndrome:** A high-yield risk when SSRIs are combined with MAO inhibitors or Tramadol.

Q: An elderly woman suffering from schizophrenia is on antipsychotic medication. She developed purposeless involuntary facial and limb movements, constant chewing and puffing of cheeks. Which of the following drugs is least likely to be involved in this side effect?

Clozapine. **Explanation:** The clinical presentation described—purposeless involuntary facial movements, constant chewing, and puffing of cheeks—is characteristic of **Tardive Dyskinesia (TD)**. This is a late-onset extrapyramidal side effect (EPS) caused by long-term blockade of dopamine (D2) receptors, leading to receptor supersensitivity. **Why Clozapine is the correct answer:** Clozapine is an atypical (second-generation) antipsychotic with a unique pharmacological profile. It has a **low affinity for D2 receptors** and a high affinity for D4 and serotonin (5-HT2A) receptors. Because it dissociates rapidly from D2 receptors, it carries the **lowest risk** of causing EPS and Tardive Dyskinesia among all antipsychotics. In fact, Clozapine is often the drug of choice for patients who have already developed TD. **Analysis of Incorrect Options:** * **Haloperidol & Fluphenazine:** These are high-potency, first-generation (typical) antipsychotics. They have a very high affinity for D2 receptors in the nigrostriatal pathway, making them the most common culprits for TD. * **Loxapine:** This is a mid-potency typical antipsychotic. While it has some serotonin-blocking properties, it behaves primarily like a first-generation drug and carries a significant risk of TD, especially in elderly patients. **Clinical Pearls for NEET-PG:** * **Risk Factors for TD:** Old age (highest risk), female gender, and long-term use of typical antipsychotics. * **Pathophysiology:** Dopamine receptor supersensitivity in the nigrostriatal pathway. * **Management:** The first step is to reduce the dose or switch to **Clozapine** or **Quetiapine**. * **Newer Treatments:** VMAT-2 inhibitors like **Valbenazine** or **Deutetrabenazine** are now FDA-approved for TD. * **Warning:** Anticholinergics (like Trihexyphenidyl) often **worsen** the symptoms of Tardive Dyskinesia, unlike acute dystonia.

Q: Which of the following indications of deep brain stimulation is not FDA approved?

Major depression. **Explanation:** Deep Brain Stimulation (DBS) involves the surgical implantation of electrodes into specific brain nuclei, connected to a pulse generator. While it is a revolutionary tool in neuromodulation, its FDA approval status varies significantly across psychiatric and neurological conditions. **Why Major Depression is the Correct Answer:** Although DBS (targeting the **Subgenual Cingulate Cortex/Area 25**) has shown promise in clinical trials for treatment-resistant depression, it is **not yet FDA-approved**. It remains an experimental treatment. In contrast, other neuromodulation techniques like ECT, rTMS, and Vagus Nerve Stimulation (VNS) *are* FDA-approved for depression. **Analysis of Incorrect Options:** * **Parkinsonism (Option C):** This was the first FDA-approved indication for DBS (1997). It typically targets the **Subthalamic Nucleus (STN)** or **Globus Pallidus interna (GPi)** to manage motor fluctuations and tremors. * **Dystonia (Option D):** Approved in 2003 under a Humanitarian Device Exemption (HDE) for chronic, intractable primary dystonia. * **OCD (Option A):** Approved in 2009 (HDE) for treatment-resistant OCD. The common target is the **Ventral Striatum** or the **Anterior Limb of the Internal Capsule (ALIC)**. **NEET-PG High-Yield Pearls:** * **DBS Targets:** * Parkinson’s: STN (most common) or GPi. * Essential Tremor: Ventral Intermediate Nucleus (Vim) of the Thalamus. * OCD: Internal Capsule/Ventral Striatum. * **FDA Status:** Remember that for psychiatric disorders, only **OCD** has FDA approval for DBS; Depression and Addiction are still under investigation. * **Contraindication:** DBS is generally avoided in patients with active psychosis or severe cognitive impairment.

Q: What is the drug of choice for a schizophrenic patient with poor oral absorption?

Clozapine. **Explanation:** The correct answer is **Clozapine**. **Why Clozapine is the Correct Choice:** The question addresses a specific pharmacokinetic challenge: **poor oral absorption**. While most antipsychotics are available in oral forms, Clozapine is unique in its pharmacological profile. In clinical scenarios where a patient fails to respond to standard antipsychotics (often due to poor absorption, high first-pass metabolism, or treatment resistance), Clozapine remains the **Gold Standard**. From a NEET-PG perspective, Clozapine is the only antipsychotic proven to be effective in **Treatment-Resistant Schizophrenia (TRS)**. If a patient has poor oral absorption leading to subtherapeutic plasma levels despite standard dosing, Clozapine is indicated because of its superior efficacy and the requirement for mandatory therapeutic drug monitoring (TDM) to ensure therapeutic levels are reached. **Analysis of Incorrect Options:** * **Haloperidol & Fluphenazine:** These are typical (first-generation) antipsychotics. While they are available as long-acting injectables (depots) to bypass the GI tract for *compliance* issues, they are not the "drug of choice" for absorption-related treatment failure. * **Olanzapine:** An atypical antipsychotic similar to Clozapine but with lower efficacy in resistant cases. It does not offer a specific advantage over Clozapine in the context of malabsorption-induced treatment failure. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine Side Effects:** Agranulocytosis (requires weekly CBC monitoring for the first 6 months), seizures (dose-dependent), myocarditis, and hypersalivation (sialorrhea). * **Indication:** Treatment-resistant schizophrenia (failure of 2 different antipsychotics for 6 weeks each) and reducing suicidal behavior in schizophrenia. * **Note:** Clozapine is the only antipsychotic that **does not** cause Tardive Dyskinesia and has minimal Extrapyramidal Side Effects (EPS).

Q: Estimation of serum levels is important for which of the following drugs?

Lithium. **Explanation:** **Lithium** is the correct answer because it has a **narrow therapeutic index**, meaning the difference between a therapeutic dose and a toxic dose is very small. Regular Therapeutic Drug Monitoring (TDM) is mandatory to ensure efficacy and prevent life-threatening toxicity. * **Why Lithium?** Lithium is not metabolized; it is excreted unchanged by the kidneys. Its serum levels are highly sensitive to hydration status, sodium intake, and drug interactions (e.g., NSAIDs, Diuretics, ACE inhibitors). The standard therapeutic range is **0.6–1.2 mEq/L**. Levels above 1.5 mEq/L are generally considered toxic. * **Why other options are incorrect:** * **Haloperidol & Chlorpromazine (Antipsychotics):** While plasma levels can be measured, they do not correlate strongly with clinical response or side effects. Dosing is primarily guided by clinical symptoms and the emergence of extrapyramidal side effects (EPS). * **Benzodiazepines:** These have a wide therapeutic window. Monitoring is based on clinical sedation and respiratory status rather than serum concentrations. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Serum Lithium levels should be measured **12 hours after the last dose** (Trough level). * **Monitoring Frequency:** Initially every 5–7 days until stable; then every 3–6 months. * **Target Levels:** * Acute Mania: 0.8–1.2 mEq/L * Maintenance: 0.6–0.8 mEq/L * Toxicity: >1.5 mEq/L (Severe toxicity >2.0 mEq/L may require hemodialysis). * **Other drugs requiring TDM in Psychiatry:** Valproate, Carbamazepine, and Clozapine (in specific refractory cases).

Q: Which of the following antismoking drugs can lead to suicidal ideation?

Varenicline. **Varenicline** is a high-yield topic in NEET-PG psychopharmacology. It is a **selective nicotinic acetylcholine receptor (nAChR) partial agonist** (specifically at the $\alpha_4\beta_2$ subtype). By partially stimulating these receptors, it reduces withdrawal symptoms, while its antagonistic property blocks the "reward" effect of nicotine if a patient relapses. ### Explanation of Options: * **Varenicline (Correct):** In 2009, the FDA issued a **Black Box Warning** (later updated but still clinically significant) regarding serious neuropsychiatric events, including **suicidal ideation**, depression, agitation, and hostility. Patients must be monitored closely for mood changes during treatment. * **Baclofen:** A $GABA_B$ agonist primarily used as a muscle relaxant. While sometimes used off-label for alcohol or cocaine dependence, it is not a primary antismoking drug and is not classically associated with suicidal ideation. * **Rimonabant:** A CB1 cannabinoid receptor antagonist. While it was used for weight loss and smoking cessation, it was withdrawn globally because it caused severe depression and anxiety, but it is not the *standard* answer for antismoking-induced suicidality in the context of current psychiatric exams compared to Varenicline. * **Naltrexone:** An opioid antagonist used primarily in alcohol and opioid dependence. It does not have a primary role in smoking cessation. ### High-Yield Clinical Pearls for NEET-PG: 1. **Mechanism of Action:** $\alpha_4\beta_2$ Nicotinic receptor partial agonist. 2. **Most Common Side Effect:** **Nausea** (often dose-dependent; taking it with food helps). 3. **Vivid Dreams:** Patients frequently report abnormal or vivid dreams. 4. **Bupropion:** Another antismoking drug (NDRI) that also carries a risk of neuropsychiatric side effects and is contraindicated in patients with a **seizure disorder** or eating disorders.

Question 1

Which of the following conditions is considered a first-line treatment for SSRI?

Accepted Answer

Social phobia

Answer

Obsessive-compulsive disorder

Answer

Panic disorder

Answer

Post-traumatic stress disorder

Question 2

Selective serotonin reuptake inhibitors are drugs of choice for all of the following conditions except:

Accepted Answer

Acute panic attack

Answer

Social phobia

Answer

Post traumatic stress disorder

Answer

Generalized anxiety disorder

Question 3

An elderly widow reports auditory hallucinations of her deceased husband speaking to her. She often discusses daily matters with him, which provokes anxiety and sadness. What is the most appropriate initial treatment for this patient?

Accepted Answer

Haloperidol

Answer

Clomipramine

Answer

Alprazolam

Answer

Electroconvulsive therapy

Question 4

A patient undergoing treatment for a psychiatric disorder takes an overdose of a drug and develops bradycardia, hypotension, decreased sweating, and salivation. What is the likely drug?

Accepted Answer

Amitriptyline

Answer

Lithium

Answer

Selegiline

Answer

Amphetamine

Question 5

An elderly woman suffering from schizophrenia is on antipsychotic medication. She developed purposeless involuntary facial and limb movements, constant chewing and puffing of cheeks. Which of the following drugs is least likely to be involved in this side effect?

Accepted Answer

Clozapine

Answer

Haloperidol

Answer

Fluphenazine

Answer

Loxapine

Question 6

Which of the following indications of deep brain stimulation is not FDA approved?

Accepted Answer

Major depression

Answer

OCD

Answer

Parkinsonism

Answer

Dystonia

Question 7

What is the drug of choice for a schizophrenic patient with poor oral absorption?

Accepted Answer

Clozapine

Answer

Haloperidol

Answer

Fluphenazine

Answer

Olanzapine

Question 8

Estimation of serum levels is important for which of the following drugs?

Accepted Answer

Lithium

Answer

Haloperidol

Answer

Benzodiazepines

Answer

Chlorpromazine

Question 9

Which of the following antismoking drugs can lead to suicidal ideation?

Accepted Answer

Varenicline

Answer

Baclofen

Answer

Rimonobant

Answer

Naltrexone

Question 10

Regarding the use of Lithium in maniac-depressive psychosis, what is the true statement?

Accepted Answer

Lithium can result in leucocytosis.

Answer

Lithium is indicated for monotherapy of acute episodes.

Answer

Monitoring of serum concentration is not useful for guiding dose adjustment.

Answer

Lithium can result in hypothyroidism on long-term use.

Psychopharmacology — MCQs

Psychopharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?